Gameto plans to integrate this meiosis-induction approach with its proprietary ovarian organoid (“ovaroid”) platform to ...

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

The complex microenvironment, or ‘ecosystem,’ within the ovary that sustains healthy follicle development and overall ovarian ...

Scientists from University of California, Los Angeles, Harvard University, and elsewhere have developed what they claim is the first comprehensive road map of how the ovarian reserve forms in primates ...

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...

A microscopy image of the outer region of the rhesus macaque ovary. The developing egg cells are marked by VASA protein (green) and surrounded by supporting granulosa cells marked by FOXL2 (magenta) ...

ARTISTRY-7 trial showed no significant survival benefit for nemvaleukin and Keytruda over chemotherapy in platinum-resistant ovarian cancer. Mural Oncology will cease nemvaleukin development for this ...

Researchers at the University of Colorado (UC) Denver, Anschutz Medical Campus, have discovered a novel combination treatment strategy that could offer new hope to ovarian cancer patients who stop ...

A drug that binds to iron and that has been FDA-approved for treating other conditions has shown promise in treating ovarian cancer in mouse models. Researchers are now designing human trials for the ...

On Tuesday, Mural Oncology plc (NASDAQ:MURA) released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) vs.